Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 433-442

  O'Callaghan, James P ^a   Sriram, Krishnan ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Biomarkers; Drug development; Drug safety assessment; Drug toxicology; Glial biomarkers; Glial fibrillary acidic protein (GFAP); Gliosis; Molecular neurotoxicology; Preclinical drug screening

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ACETYLPYRIDINE; 3,3' IMINODIPROPIONITRILE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5,7 DIHYDROXYTRYPTAMINE; BILIRUBIN; CADMIUM; CD11B ANTIGEN; COLCHICINE; DICHLOBENIL; DIZOCILPINE; DOMOIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; KAINIC ACID; KETAMINE; METHAMPHETAMINE; METHYLAZOXYMETHANOL; METHYLMERCURY; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDOPAMINE; PROTEIN S 100; STAT3 PROTEIN; TRIETHYLTIN; TRIMETHYLTIN;

ASTROCYTE; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SAFETY; GLIOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROGLIA; NERVOUS SYSTEM INJURY; NEUROTOXICITY; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOXICITY TESTING; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DRUG EVALUATION, PRECLINICAL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HUMANS; NERVOUS SYSTEM; PHARMACEUTICAL PREPARATIONS; SAFETY; SENSITIVITY AND SPECIFICITY; TOXICITY TESTS;

EID: 19444378229     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.433     Document Type: Review

References (31)

1. SUTCLIFFE JG: mRNA in the mammalian central nervous system. Ann. Rev. Neurosci. (1988) 11:157-1998.
2. O'CALLAGHAN JP, JENSEN KF: Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. Neurotoxicology (1992) 13(1):113-122.
3. O'CALLAGHAN JP: Quantitative features of reactive gliosis following toxicant-induced damage of the CNS. Ann. NY Acad. Sci. (1993) 679:195-210.
4. O'CALLAGHAN JP, JENSEN KF, MILLER DB: Quantitative aspects of drug and toxicant-induced astrogliosis. Neurochem. Int. (1995) 26(2):115-124.
5. LITTLE AR, O'CALLAGHAN JP: Astrogliosis in the adult and developing CNS: is there a role for proinflammatory cytokines? Neurotoxicology (2001) 22(5):607-618.
6. LITTLE AR, BENKOVIC SA, MILLER DB, O'CALLAGHAN JP: Chemically induced neuronal damage and gliosis: enhanced expression of the proinflammatory chemokine, monocyte chemoattractant protein (MCP)-1, without a corresponding increase in proinflammatory cytokines (1). Neuroscience (2002) 115(1):307-320.
7. SRIRAM K, MATHESON JM, BENKOVIC SA et al.: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. (2002) 16(11):1474-1476
8. SRIRAM K, BENKOVIC SA, HEBERT MA; MILLER DB, O'CALLAGHAN JP: Induction of gp 130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo? J. Biol. Chem. (2004) 279(19):19936-19947.
9. SRIRAM K, O'CALLAGHAN JP: Signaling mechanisms underlying toxicant-induced gliosis. In: The Role of Glia in Neurotoxicity (2nd Ed). Aschner M, Costa LG (Eds), CRC Press, Boca Raton, Florida (2005) pp 141-171.
10. GROSS CJ, KRAMER JA: The role of investigative molecular toxicology in early stage drug development. Expert Opin. Drug Saf. (2003) 2(2):147-159.
11. IRWIN S: Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (1968) 13(3):222-257.
12. GERBER GJ, O'SHAUGHNESSY D: Comparison of the behavioral effects of neurotoxic and systemically toxic agents; how discriminatory are behavioral tests of neurotoxicity? Neurobehav. Toxicol. Teratol. (1986) 8(6):703-710.
13. SHEETS LP, HAMILTON BF, SANGHA GK, THYSSEN JH: Subchronic neurotoxiciry screening studies with six organophosphate insecticides: an assessment of behavior and morphology relative to cholinesterase inhibition. Fundam. Appl. Toxicol. (1997) 35(1):101-119.
14. MIDDAUGH LD, DOW-EDWARDS D, LI AA et al.: Neurobehavioral assessment: a survey of use and value in safety assessment studies. Toxicol Sci. (2003) 76(2):250-261.
15. SWITZER RC 3rd: Application of silver degeneration stains for neurotoxicity testing. Toxicol. Pathol. (2000) 28(1):70-83.
16. GUNDERSEN HJ: Stereology: the fast lane between neuroanatomy and brain function - or still only a tightrope? Acta Neurol. Scand. Suppl. (1992) 137:8-13.
17. SCHMITZ C, HOF PR: Design-based stereology in neuroscience. Neuroscience (2005) 130(4):813-831.
18. DE OLMOS JS, BELTRAMINO CA, DE OLMOS DE LORENZO S: Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicol. Teratol. (1994) 16(6):545-561.
19. SCHMUED LC, HOPKINS KJ: Fluoro-Jade B: A high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. (2000) 874(2):123-130.
20. SCHMUED LC, HOPKINS KJ: Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol. Pathol. (2000) 28(1):91-99.
21. LORD PG, PAPOIAN T: Genomics and drug toxicity. Science (2004) 306(5696):575.
22. RIDET JL, MALHOTRA SK, PRIVAT A, GAGE FH: Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. (1997) 20(12):570-577.
23. NORENBERG MD: The reactive astrocyte. In: The Role of Glia in Neurotoxicity (2nd Ed). Aschner M, Costa LG (Eds), CRC Press, Boca Raton, Florida (2005) 73-92.
24. NORTON WT, AQUINO DA, HOZUMI I, CHIU FC, BROSNAN CF: Quantitative aspects of reactive gliosis: a review. Neurochem. Res. (1992) 17(9):877-885.
25. O'CALLAGHAN JP: Quantification of glial fibrillary acidic protein: comparison of slot-immunobinding assays with a novel sandwich ELISA. Neurotoxicol. Teratol. (1991) 13(3):275-281.
26. O'CALLAGHAN JP: Measurement of glial fibrillary acidic protein. In: Current Protocols in Toxicology. Maines MD, Costa LG, Hodgson E, Reed DJ, Sipes IG (Eds). John Wiley & Sons, New York (2002) Sections 12.8.1-12.8.12.
27. KASHON ML, ROSS GW, O'CALLAGHAN JP et al.: Associations of cortical astrogliosis with cognitive performance and dementia status. J. Alzheimers Dis. (2004) 6(6):595-604.
28. KREUTZBERG GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci. (1996) 19(8):312-318.
29. STREIT WJ: The role of microglia in neurotoxicity. In: The Role of Glia in Neurotoxicity (2nd Ed). Aschner M, Costa LG (Eds), CRC Press, Boca Raton, Florida (2005) 29-40.
30. MILLER DB, REINHARD JF Jr, DANIELS AJ, O'CALLAGHAN JP: Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J. Neurochem. (1991) 57:541-549.
31. Committee on Animal and Translational Neuroscience: Translational neuroscience accomplishments, Society for Neuroscience, 2003.